| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
64,478 |
50,778 |
$1.95M |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
15,414 |
14,061 |
$210K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
4,676 |
4,299 |
$199K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
3,655 |
3,347 |
$158K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
2,009 |
1,958 |
$112K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
6,860 |
5,772 |
$92K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
1,732 |
1,670 |
$84K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
6,370 |
4,773 |
$75K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
2,366 |
2,141 |
$55K |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
3,361 |
3,252 |
$53K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
957 |
921 |
$52K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
659 |
634 |
$36K |
| 90461 |
|
3,367 |
2,113 |
$34K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
474 |
466 |
$30K |
| 95117 |
|
2,084 |
925 |
$20K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
607 |
546 |
$19K |
| 83655 |
|
1,838 |
1,800 |
$18K |
| 87807 |
|
1,568 |
1,467 |
$18K |
| 99441 |
|
608 |
561 |
$16K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
1,254 |
674 |
$16K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
560 |
535 |
$7K |
| 95115 |
|
658 |
284 |
$5K |
| 85018 |
|
2,411 |
2,334 |
$4K |
| 90472 |
Immunization administration, each additional vaccine (list separately) |
276 |
231 |
$3K |
| 81025 |
|
292 |
281 |
$2K |
| 99383 |
|
27 |
27 |
$2K |
| 74018 |
|
169 |
93 |
$1K |
| 90670 |
|
968 |
944 |
$1K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
38 |
35 |
$1K |
| 90734 |
|
156 |
153 |
$1K |
| 90633 |
|
822 |
805 |
$1K |
| 90680 |
|
574 |
566 |
$899.30 |
| 92587 |
|
38 |
37 |
$842.14 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
1,279 |
1,176 |
$836.82 |
| 81003 |
|
1,982 |
1,845 |
$737.85 |
| 90649 |
|
171 |
170 |
$709.32 |
| 90686 |
|
357 |
348 |
$580.03 |
| 90688 |
|
39 |
39 |
$564.56 |
| 90619 |
|
125 |
125 |
$555.48 |
| 99050 |
|
34 |
34 |
$457.00 |
| 0002A |
|
21 |
21 |
$400.00 |
| 90648 |
|
809 |
798 |
$393.75 |
| 90723 |
|
309 |
304 |
$340.64 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
97 |
80 |
$335.63 |
| 86308 |
|
71 |
66 |
$329.06 |
| 90715 |
|
147 |
145 |
$320.79 |
| 99051 |
|
12 |
12 |
$202.50 |
| 93000 |
|
13 |
13 |
$190.51 |
| 90710 |
|
47 |
47 |
$136.77 |
| 73630 |
|
12 |
12 |
$133.32 |
| 90685 |
|
28 |
28 |
$41.63 |
| 90700 |
|
28 |
28 |
$17.86 |
| 90677 |
|
249 |
247 |
$2.13 |
| 3074F |
|
86 |
76 |
$0.73 |
| 1125F |
|
44 |
40 |
$0.32 |
| 90716 |
|
30 |
30 |
$0.30 |
| 1126F |
|
29 |
28 |
$0.27 |
| 3078F |
|
32 |
26 |
$0.24 |
| 90707 |
|
20 |
20 |
$0.19 |
| 90696 |
|
15 |
15 |
$0.14 |
| 1159F |
|
633 |
550 |
$0.10 |
| 1160F |
|
633 |
550 |
$0.10 |
| 3077F |
|
15 |
12 |
$0.09 |
| 1111F |
|
293 |
265 |
$0.02 |
| G9902 |
Patient screened for tobacco use and identified as a tobacco user |
1,132 |
982 |
$0.00 |
| G8754 |
Most recent diastolic blood pressure < 90 mmhg |
1,205 |
1,128 |
$0.00 |
| 1036F |
|
1,348 |
1,171 |
$0.00 |
| G9906 |
Patient identified as a tobacco user received tobacco cessation intervention during the measurement period or in the six months prior to the measurement period (counseling and/or pharmacotherapy) |
1,126 |
978 |
$0.00 |
| 3014F |
|
14 |
13 |
$0.00 |
| J3420 |
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg |
86 |
40 |
$0.00 |
| G8420 |
Bmi is documented within normal parameters and no follow-up plan is required |
109 |
95 |
$0.00 |
| 1034F |
|
66 |
58 |
$0.00 |
| G8755 |
Most recent diastolic blood pressure >= 90 mmhg |
76 |
73 |
$0.00 |
| 3017F |
|
43 |
41 |
$0.00 |
| 91307 |
|
46 |
38 |
$0.00 |
| G8752 |
Most recent systolic blood pressure < 140 mmhg |
1,015 |
951 |
$0.00 |
| 4004F |
|
2,129 |
1,881 |
$0.00 |
| G8783 |
Normal blood pressure reading documented, follow-up not required |
1,754 |
1,556 |
$0.00 |
| G8483 |
Influenza immunization was not administered for reasons documented by clinician (e.g., patient allergy or other medical reasons, patient declined or other patient reasons, vaccine not available or other system reasons) |
138 |
123 |
$0.00 |
| G8753 |
Most recent systolic blood pressure >= 140 mmhg |
358 |
338 |
$0.00 |
| G8482 |
Influenza immunization administered or previously received |
1,185 |
1,015 |
$0.00 |
| G8417 |
Bmi is documented above normal parameters and a follow-up plan is documented |
15 |
14 |
$0.00 |